Original Article

Clinical Research

Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project

  • Prostate Cancer and Prostatic Diseases volume 20, pages 4854 (2017)
  • doi:10.1038/pcan.2016.39
  • Download Citation
Received:
Revised:
Accepted:
Published online:

Abstract

Background:

Epidemiologic and laboratory evidence supports a role for cholesterol in prostate cancer (PC). Dietary saturated fat content impacts serum cholesterol levels. However, epidemiologic associations between saturated fat and PC aggressiveness are inconsistent. We hypothesized that high saturated fat intake would be associated with increased PC aggressiveness, and that statin use would modify this association.

Methods:

Of 1854 PC cases in the North Carolina-Louisiana PC Project, 321 (17%) were classified as high aggressive (Gleason sum 8, PSA>20 ng ml−1, or Gleason sum 7 and clinical stage T3-4) or low/intermediate aggressive (all other cases). Using low/intermediate aggressive cases as the referent group, we examined the association between tertiles of total fat-adjusted saturated fat intake and high aggressive PC using logistic regression, overall and stratified by race and statin use. We examined total fat-adjusted polyunsaturated and monounsaturated fatty acids (PUFA and MUFA, respectively), trans fat and cholesterol intake in secondary analysis.

Results:

High total fat-adjusted saturated fat intake was associated with an elevated odds ratio (OR) for aggressive PC (ORT3vsT1 1.51; 95% CI 1.10–2.06; P-trend=0.009), with an attenuated association in statin users (ORT3vsT1 1.16; 95% CI 0.67–2.01; P-trend=0.661) compared with non-users (ORT3vsT1 1.71; 95% CI 1.16–2.51; P-trend=0.053). High total fat-adjusted cholesterol intake was associated with aggressive PC in European Americans (ORT3vsT1 1.62; 95% CI 1.02–2.58; P-trend=0.056), but not African Americans (ORT3vsT1 0.92; 95% CI 0.60–1.42; P-trend=0.750). High total fat-adjusted PUFA was inversely associated with PC aggressiveness (ORT3vsT1 0.75; 95% CI 0.55–1.03), although this was not significant. No associations were found between total fat-adjusted MUFA or trans fat and PC aggressiveness.

Conclusions:

High total fat-adjusted saturated fat intake was associated with increased PC aggressiveness, with a suggestion of a stronger effect in men not using statins. The association between total fat-adjusted cholesterol intake and PC aggressiveness was most pronounced in European Americans.

  • Subscribe to Prostate Cancer and Prostatic Diseases for full access:

    $444

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    , , , , , et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079–1092.

  2. 2.

    , , , , , et al. Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys. BMJ 2014; 348: g2272.

  3. 3.

    , , , , , et al. Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. Cancer Res 2008; 68: 3066–3073.

  4. 4.

    , . Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer 2015; 22: R365–R386.

  5. 5.

    , , , , . Fat and meat intake and prostate cancer risk: the multiethnic cohort study. Int J Cancer 2007; 121: 1339–1345.

  6. 6.

    , , , , , et al. Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 2010; 172: 566–577.

  7. 7.

    , , , , , . Fat intake is not linked to prostate cancer: a systematic review and dose-response meta-analysis. PLoS One 2015; 10: e0131747.

  8. 8.

    , , , . Dietary fat, fatty acids, and risk of prostate cancer in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev 2013; 22: 697–707.

  9. 9.

    , , , , , et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993; 85: 1571–1579.

  10. 10.

    , , , , , et al. Dietary fatty acid intake and prostate cancer survival in Orebro County, Sweden. Am J Epidemiol 2012; 176: 240–252.

  11. 11.

    , , , , , et al. Fat intake after prostate cancer diagnosis and mortality in the Physicians' Health Study. Cancer Causes Control 2015; 26: 1117–1126.

  12. 12.

    , . Causes of high blood cholesterol. Circulation 1990; 81: 412–427.

  13. 13.

    , , , , , et al. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 2014; 114: 661–666.

  14. 14.

    , , , , , et al. Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH Database. Cancer Epidemiol Biomarkers Prev 2014; 23: 2349–2356.

  15. 15.

    , , , , , et al. Statin use and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project. Cancer Epidemiol Biomarkers Prev 2016.

  16. 16.

    , , , , , et al. The North Carolina-Louisiana Prostate Cancer Project (PCaP): methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes. Prostate 2006; 66: 1162–1176.

  17. 17.

    , , , , , et al. Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires: the Eating at America's Table Study. Am J Epidemiol 2001; 154: 1089–1099.

  18. 18.

    , , , , , et al. Cognitive research enhances accuracy of food frequency questionnaire reports: results of an experimental validation study. J Am Diet Assoc 2002; 102: 212–225.

  19. 19.

    , . Total energy intake: implications for epidemiologic analyses. Am J Epidemiol 1986; 124: 17–27.

  20. 20.

    , , , , , et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995; 87: 652–661.

  21. 21.

    , , , , , et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8: 25–34.

  22. 22.

    , , , , , et al. Meat consumption among Black and White men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2006; 15: 211–216.

  23. 23.

    . Effects of dietary fat on androgen secretion and metabolism. Reprod Biol 2006; 6 (Suppl 2): 13–20.

  24. 24.

    , , , , , . Inflammatory signaling involved in high-fat diet induced prostate diseases. J Urol Res 2015; 2; pii: 1018.

  25. 25.

    , . The role of dietary fat throughout the prostate cancer trajectory. Nutrients 2014; 6: 6095–6109.

  26. 26.

    , , , . Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003; 77: 1146–1155.

  27. 27.

    , , , , , et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2009; 18: 2807–2813.

  28. 28.

    , , , , , et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819–1825.

  29. 29.

    , , , , . Oxidative balance score and risk of prostate cancer: results from a case-cohort study. Cancer Epidemiol 2011; 35: 353–361.

  30. 30.

    , , , , , . Systematic review of prostate cancer risk and association with consumption of fish and fish-oils: analysis of 495,321 participants. Int J Clin Pract 2015; 69: 87–105.

  31. 31.

    , , , , , et al. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 2814–2821.

Download references

Acknowledgements

We thank the staff, advisory committees and research subjects participating in the PCaP study for their important contributions. This work was supported by the American Institute for Cancer Research (to EHA). The North Carolina-Louisiana Prostate Cancer Project (PCaP) was funded by the Department of Defense contract DAMD 17-03-2-0052.

Author information

Affiliations

  1. Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    • E H Allott
    •  & J T Bensen
  2. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    • E H Allott
    • , L Farnan
    • , J L Mohler
    •  & J T Bensen
  3. David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

    • L Arab
  4. Winthrop P Rockefeller Cancer Institute and College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    • L J Su
  5. School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA

    • E T H Fontham
  6. Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA

    • J L Mohler
  7. Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    • J L Mohler
  8. Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, USA

    • S E Steck

Authors

  1. Search for E H Allott in:

  2. Search for L Arab in:

  3. Search for L J Su in:

  4. Search for L Farnan in:

  5. Search for E T H Fontham in:

  6. Search for J L Mohler in:

  7. Search for J T Bensen in:

  8. Search for S E Steck in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to E H Allott.

Supplementary information

Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website (http://www.nature.com/pcan)